Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCI) Nasal Spray Shelf Life Extension to 36 Months


Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the shelf life of NARCAN® (naloxone HCl) Nasal Spray from 24 months to 36 months. Narcan Nasal Spray was the first intranasal form of naloxone approved by FDA and Health Canada for the emergency treatment of known or suspected opioid overdose.

“Emergent is pleased to receive FDA approval of the shelf life extension for NARCAN® Nasal Spray,” said Doug White, SVP and devices business unit head at Emergent. “This is an example of our continued efforts to innovate and improve product features designed to address the needs of patients, consumers, health care providers, pharmacists, and first responders.”

In early July, the company launched the Generation II NARCAN® Nasal Spray device, which is identified by a red plunger and enhances temperature excursions and storage below 25°C.

Read more about this news here.

Related articles

Recent articles